i2o Therapeutics is pioneering the use of Ionic Liquids (ILs) for therapeutic development. i2o’s wholly-owned pipeline consists of first-in-class and best-in-class transformative oral biologics with improved clinical benefits and a superior safety profile over current standard of care. With an initial focus on metabolic and inflammatory diseases, i2o is delivering on the promise of oral biologics—considered the “holy grail biologic opportunity” by the pharmaceutical industry.
By accessing technology developed at Harvard University, we are redefining the patient experience by combining the convenience of oral medication with the superior clinical benefits of biologics.
We do this by pairing a world-renowned team of chemical engineers, bioengineers, and biologists with experienced industry veterans having developed and launched over 15 blockbuster products.